Abstract
ObjectiveTo compare the effectiveness of ocrelizumab with interferon-β, fingolimod and natalizumab in relapsing-remitting multiple sclerosis (MS).MethodUsing the MSBase registry, we identified patients with relapsing-remitting MS treated for >=6 months with...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
